Searching for early breast cancer biomarkers by serum protein profiling of pre-diagnostic serum; A nested case-control study
BMC Cancer, 08/29/2011
Opstal-van Winden AWJ et al.
– The authors show that serum protein profiles are already altered up to three years before breast cancer detection.
Nested case-control design we compared 68 women diagnosed with breast cancer within 3 years after enrollment, with 68 matched controls for differences in serum protein profiles
All samples were analyzed with SELDI-TOF MS (surface enhanced laser desorption/ionization time-of-flight mass spectrometry)
Subset of 20 case-control pairs
Serum proteome identified and relatively quantified using isobaric Tags for Relative and Absolute Quantification (iTRAQ) and online two-dimensional nano-liquid chromatography coupled with tandem MS (2D-nanoLC-MS/MS)
2 SELDI-TOF MS peaks with m/z 3323 and 8939, which probably represent doubly charged apolipoprotein C-I and C3a des-arginine anaphylatoxin (C3adesArg), higher in pre-diagnostic breast cancer serum (p=0.02 and p=0.06)
With 2D-nanoLC-MS/MS, afamin, apolipoprotein E and isoform 1 of inter-alpha trypsin inhibitor heavy chain H4 (ITIH4) found to be higher in pre-diagnostic breast cancer (p<0.05), while alpha-2-macroglobulin and ceruloplasmin were lower (p<0.05)
C3adesArg and ITIH4 have previously been related to presence of symptomatic and/or mammographically detectable breast cancer
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.